These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9272370)

  • 1. Regulatory and standardization issues.
    Winsnes R
    Dev Biol Stand; 1997; 89():349-50. PubMed ID: 9272370
    [No Abstract]   [Full Text] [Related]  

  • 2. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
    Beloradsky BH
    Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
    [No Abstract]   [Full Text] [Related]  

  • 3. A consideration of control requirements for acellular pertussis vaccines.
    Corbel MJ; Xing DK
    Dev Biol Stand; 1997; 89():343-7. PubMed ID: 9272369
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy trial of acellular pertussis vaccines; trial I.
    Olin P
    Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569
    [No Abstract]   [Full Text] [Related]  

  • 5. The Gothenburg pertussis vaccine study.
    Trollfors B; Taranger J
    Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
    [No Abstract]   [Full Text] [Related]  

  • 6. Pertussis vaccines for adolescents and adults.
    Cherry JD
    Pediatrics; 2005 Sep; 116(3):755-6. PubMed ID: 16140719
    [No Abstract]   [Full Text] [Related]  

  • 7. Japanese experience with 60 million doses of acellular pertussis vaccines.
    Sato H
    Dev Biol Stand; 1997; 89():327-9. PubMed ID: 9272367
    [No Abstract]   [Full Text] [Related]  

  • 8. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccines: the next step.
    Halperin SA
    Dev Biol Stand; 1997; 89():363-5. PubMed ID: 9272372
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of acellular pertussis vaccine: follow-up studies.
    Chen RT
    Dev Biol Stand; 1997; 89():373-5. PubMed ID: 9272374
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccine trials. Trial synopses.
    Dev Biol Stand; 1997; 89():37-47. PubMed ID: 9333567
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health application of acellular pertussis vaccines.
    Hadler SC; Orenstein WA
    Dev Biol Stand; 1997; 89():355-61. PubMed ID: 9272371
    [No Abstract]   [Full Text] [Related]  

  • 15. Preventing pertussis in infants by vaccinating adults.
    Finger R; Shoemaker J
    Am Fam Physician; 2006 Aug; 74(3):382. PubMed ID: 16913156
    [No Abstract]   [Full Text] [Related]  

  • 16. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis.
    Schmitt HJ
    Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vaccine protection of Swedish children. Time for revision of replacing doses of diphtheria, tetanus, polio and pertussis].
    Olin P
    Lakartidningen; 2001 Aug; 98(35):3654-7. PubMed ID: 11577639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.